EP300 and prostate carcinoma: Here they report CBP/p300-interacting transactivator with E/D-rich carboxy-terminal domain-2 (CITED2) to interact with nucleolin, p300, and PRMT5 subunits, and reveal a role of CITED2-nucleolin axis in prostate cancer metastasis.